Doern G V, Pfaller M A, Erwin M E, Brueggemann A B, Jones R N
Department of Pathology, University of Iowa College of Medicine, Iowa City 52242, USA.
Diagn Microbiol Infect Dis. 1998 Dec;32(4):313-6. doi: 10.1016/s0732-8893(98)00081-9.
As part of the SENTRY antimicrobial resistance surveillance program, a total of 1100 clinically significant respiratory tract isolates of Streptococcus pneumoniae were tested for susceptibility to six fluoroquinolone antimicrobial agents: ciprofloxacin, levofloxacin, gatifloxacin, grepafloxacin, sparfloxacin, and trovafloxacin. Isolates were obtained during the 5-month period, February to June, 1997 from 27 United States medical center laboratories and seven laboratories in Canadian health care institutions. All testing was performed in a single center. Of 1100 test strains, 3 (0.3%), all from different U.S. centers, were fluoroquinolone resistant. Among the remaining 1097 fluoroquinolone-susceptible isolates, the rank order of activity among the six agents tested in this study was grepafloxacin (modal MIC = 0.25 microgram/mL) = trovafloxacin (modal MIC = 0.25 microgram/mL) = sparfloxacin (0.25 microgram/mL) > gatifloxacin (0.5 microgram/mL) > levofloxacin (1 microgram/mL) = ciprofloxacin (1 microgram/mL). Fluoroquinolone resistance is currently uncommon among respiratory tract isolates of S. pneumoniae in North America, but there exist clear differences between the in vitro activities of different fluoroquinolones for this organism.
作为哨兵抗菌药物耐药性监测计划的一部分，共对1100株具有临床意义的肺炎链球菌呼吸道分离株进行了六种氟喹诺酮类抗菌药物的敏感性测试，这六种药物分别为环丙沙星、左氧氟沙星、加替沙星、格帕沙星、司帕沙星和曲伐沙星。分离株于1997年2月至6月这5个月期间，从美国27家医学中心实验室和加拿大医疗机构的7家实验室获得。所有检测均在单一中心进行。在1100株测试菌株中，有3株（0.3%）对氟喹诺酮耐药，这3株均来自不同的美国中心。在其余1097株对氟喹诺酮敏感的分离株中，本研究中所测试的六种药物的活性排序为：格帕沙星（最低抑菌浓度众数=0.25微克/毫升）=曲伐沙星（最低抑菌浓度众数=0.25微克/毫升）=司帕沙星（0.25微克/毫升）>加替沙星（0.5微克/毫升）>左氧氟沙星（1微克/毫升）=环丙沙星（1微克/毫升）。目前在北美的肺炎链球菌呼吸道分离株中，氟喹诺酮耐药并不常见，但不同氟喹诺酮类药物对该菌的体外活性存在明显差异。
